FDA grants orphan drug designation for Inflazome’s Inzomelid to treat cryopyrin-associated periodic syndromes
Orphan Drug Designation is an important regulatory milestone granted to drugs that are intended to treat rare diseases and conditions, such as CAPS. CAPS is a rare, autoinflammatory